Clostridial neurotoxins

Neurology in Practice

Volumn 75, Issue 3, 2004, Pages

  Goonetilleke, A ^a   Harris, J B ^b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTITOXIN; BACLOFEN; BACTERIAL TOXIN; BOTULINUM TOXIN; CHLORAMPHENICOL; CLINDAMYCIN; DANTROLENE; DOXYCYCLINE; ERYTHROMYCIN; MAGNESIUM DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; NEUROTOXIN; PENICILLIN G; QUININE; TETANUS TOXOID; TETRACYCLINE; VANCOMYCIN; DIAMORPHINE; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; TETANUS TOXIN;

BIOLOGICAL WARFARE; BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM TETANI; CONVULSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEVER; FOOD CONTAMINATION; HUMAN; HYPERHIDROSIS; HYPERTENSION; INCUBATION TIME; INOCULATION; MASSETER MUSCLE; MUSCLE SPASM; NERVE PARALYSIS; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; OPISTHOTONUS; PRIORITY JOURNAL; REVIEW; RIGIDITY; SEIZURE; TACHYCARDIA; TETANUS; TETANUS PROPHYLAXIS; VOMITING; WORLD HEALTH ORGANIZATION; AUTONOMIC NERVOUS SYSTEM; DRUG ABUSE; NERVE ENDING; NEWBORN TETANUS; SIDE EFFECT; TOXIN SYNTHESIS;

BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM TETANI; HUMANS; TETANUS; TETANUS TOXIN;

EID: 4344630056     PISSN: 14737086     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.046102     Document Type: Review

References (12)

1. Meunier FA, Herreros J, Schiavo G, et al. Molecular mechanisms of action of botulinal neurotoxins and the synoptic remodelling they induce in vivo at the skeletal neuromuscular junction. In: Massaro EJ, ed. Handbook of neurotoxicology, vol I. Totowa, New Jersey: Humana Press, 2002:305-47. An excellent review on the mechanisms of action of the neurotoxins discussed.
2. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995;332:761-6.
3. Farrer JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry 2000;69:292-301. Excellent review article containing information on the structure and action of the tetanus toxin, the clinical features of tetanus, and useful details on the management of the condition.
4. Thwaites CL. Tetanus. Practical Neurology 2002;2(3):130-7. Recent article containing useful information on the clinical features and management of tetanus.
5. Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998;279:859-63.
6. Wemer SB, Passaro D, McGee J, et al. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis 2000;31:1018-24.
7. Spiko JS, Schaffer N, Hargrett-Bean N, et al. Risk factors for infant botulism in the United States. Am J Dis Child 1989;143:828-32.
8. Schmidt RD, Schmidt TW. Infant botulism: a case series and review of the literature. J Emerg Med 1992;10:713-8.
9. Coleman EA, Yergler ME. Botulism. Am J Nursing 2002;102(9):44-7. A good introductory article for the reader interested in the bioterrorist aspects of botulinum toxin.
10. Cherington M, Clinical spectrum of botulism. Muscle Nerve 1998;21:701-10.
11. Guiterrez AR, Bodensteiner J, Gutmann L. Electrodiagnosis of infant botulism. J Child Neurol 1994;9:362-5.
12. American Academy of Pediatrics. Clostridial infections. In: Pickering LK, ed. 2000 Red book: report of the Committee on Infectious Diseases, 25th ed. Elk Grove Village, Illinois: Academy of Pediatrics, 2000:212-4.